On 29 September 2026, China Shineway Pharmaceutical Group Limited (Shineway Pharmaceutical) announced the composition of its Board of Directors and committee assignments that will take effect on 1 October 2026.

The refreshed Board will consist of six members: Executive Directors Li Zhenjiang and Li Huimin; Independent Non-executive Directors Liu Shun Fai, Yew Yat On and Wang Guihua; and Non-executive Director Zhou Wencheng.

Four specialised committees will continue to support the Board’s oversight functions. • Audit Committee: chaired by Independent Non-executive Director Liu Shun Fai. • Nomination Committee: chaired by Independent Non-executive Director Liu Shun Fai, with Executive Director Li Huimin and Independent Non-executive Directors Yew Yat On and Wang Guihua serving as members. • Remuneration Committee: chaired by Independent Non-executive Director Wang Guihua, joined by Executive Director Li Huimin and Independent Non-executive Director Yew Yat On. • Corporate Social Responsibility and Sustainability Committee: chaired by Independent Non-executive Director Liu Shun Fai, with Independent Non-executive Directors Yew Yat On and Wang Guihua as members.

Executive Director Li Zhenjiang will serve as Chairman of the full Board, while committee leadership is predominantly assigned to independent directors, underscoring Shineway Pharmaceutical’s emphasis on independent oversight across audit, nomination, remuneration, and sustainability matters.